Cadila granted US FDA approval to market antidepressant
Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection
Japan M&A By the Numbers: Q4 2023
Essential IR Insights Newsletter Fall - 2023
A Corporation Clearly Pinpoints Activist Investor Activity
The U.S. Food and Drug Administration granted Cadila Healthcare Ltd. approval to market a generic version of an antidepressant drug.
The Indian pharmaceutical company will market mirtazapine in three doses, which will be produced at its manufacturing facility in Baddi, India.
